The pilot study of nivolumab for advanced NSCLC patients with IIPs which is clinically considered to be at low risk of acute exacerbation of IIPs.
Phase of Trial: Phase I
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 14 Feb 2017 Status changed from recruiting to completed.
- 30 May 2016 New trial record